The combination of immune checkpoint inhibitors ipilimumab and nivolumab has been
recently been FDA approved for first line treatment of unresectable and metastatic BRAF wild type
melanoma. The approval came following the impressive results of the CheckMate 067, where the
combination of ipilimumab and nivolumab appeared to outperform each as a single agent in regards to
response rate and progression free survival. Though we await final overall survival data, the
combination will likely be adapted by many oncologists and integrated into the ever changing
melanoma treatment algorithm. In this article we aim to summarize the data leading up to the recent
FDA approval and publication by Larkin et al. that presents the results from the CheckMate 067 trial.
We will also further explore the feasibility, challenges, and applicability of combination immune
checkpoint inhibitor therapy.
Keywords: Anti-CTLA-4, anti-PD-1, ipilimumab, melanoma, nivolumab.
Rights & PermissionsPrintExport